Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FUTURE platform trial of futibatinib combinations in colorectal and other solid tumors
2024-517573-24-00Phase 2Authorised
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Dec 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of futibatinib in colorectal cancer (CRC) and Nonhematologic neoplasms, sponsored by Institut für Klinische Krebsforschung. Primary endpoint: Objective response rate. Planned start Dec 2025; status: authorised.
02
Drugs
futibatinib
03
Conditions
colorectal cancer (CRC)Nonhematologic neoplasms
Beyond the preview
Go deeper on 2024-517573-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517573-24-00.